ACADIA Pharmaceuticals Inc. (ACAD)

Wie das Geld verdient wird

All revenue is net product sales of prescription medicines; the 2025 income statement shows no collaboration or royalty line. ACADIA does not sell to patients or pharmacies at large. NUPLAZID goes to a small number of specialty pharmacies, which dispense on prescription, and specialty distributors, which resell to government facilities, long-term care pharmacies and hospital in-patient pharmacies. DAYBUE is sold in the US to a single wholesale distributor with specialty pharmacy services, and outside the US through third-party distributors. Third-party logistics providers handle warehousing, order-taking, invoicing, collections and returns. What the company actually books is gross price less a large set of deductions — Medicaid and Medicare Part D rebates, inflation-cap rebates under the Inflation Reduction Act, distribution fees, chargebacks, prompt-pay discounts, co-pay assistance — and those gross-to-net adjustments are estimates that get trued up later. In December 2025 that mechanism bit: the first CMS invoices for Medicare inflation-cap rebates covering October 2022 to September 2024 came in higher than accrued, producing an unfavourable $20.1 million adjustment that reduced reported NUPLAZID net sales without any change in underlying demand. Manufacturing is fully outsourced to contract manufacturers such as Corden, FIS, Flamma, Patheon, Bend and Halo.

Umsatz nach Segment

Both products are protected by patents and by being the only FDA-approved option in their indication — NUPLAZID the first and only approved drug for Parkinson's disease psychosis, DAYBUE the first and only approved treatment for Rett syndrome. ACADIA holds 25 US patents relating to pimavanserin, nine of them Orange Book-listed; the composition-of-matter patent expires in 2030 with its granted term extension, while the polymorph and method-of-use patents run out between 2026 and 2028, with later formulation patents to 2037 and 2038. For trofinetide it holds exclusive licences to seven US patents from Neuren, with the Rett syndrome use patent expiring in 2032 and potentially extendable to January 2036. The advantage is real but bounded and contested. Generic filers have submitted ANDAs for NUPLAZID: ACADIA won at the District Court against MSN and Aurobindo and the Federal Circuit affirmed one judgment in June 2025, but a second appeal was still pending with briefing completed in December 2025. Neither product enjoys a moat from switching costs or scale — NUPLAZID competes with cheap generic antipsychotics used off-label, and DAYBUE with off-label symptomatic treatments and several Rett programmes in development.

Demand comes from how many people have Parkinson's disease psychosis or Rett syndrome, how many get diagnosed and prescribed, and how long they stay on therapy — not from the state of the economy. These are severe chronic conditions and the medicines are reimbursed prescription drugs, so volumes hold up through a downturn. What actually moves revenue is the number of prescribers reached, patient persistency, and the size of the gross-to-net deductions. The company itself describes its growth levers in those terms: a larger field force, direct-to-consumer campaigns, real-world evidence, and for DAYBUE new patient adoption plus the STIX powder formulation launched in the first quarter of 2026. Note that reported revenue can be defensive in volume terms and still fall in dollar terms if payor pressure widens the gap between gross and net price, as the $20.1 million IRA rebate adjustment showed in 2025. The company also lists unfavourable global economic conditions as a risk factor, without quantifying the effect.

Wichtigste Risiken

• Everything depends on two commercial products — The company states that its prospects are highly dependent on the successful commercialisation of its products, and that to the extent it cannot establish, maintain or increase sales of them, its business, financial condition and results of operations may be materially adversely affected and the share price may decline.
• Coverage and reimbursement by payors — ACADIA discloses that its ability to generate product revenues will be diminished if coverage from commercial or government payors is not provided or is decreased, or if patients face unacceptably high out-of-pocket costs. It notes that products under the Medicare Drug Price Negotiation Program are expected to see a significant per-unit reduction in reimbursement, and that on current law 2029 is the earliest year NUPLAZID could be subject to a negotiated price, having expected to qualify for the small biotech exception.
• Dependence on a narrow distribution network — The filing states that the company relies on a limited network of third-party distributors and pharmacies to market and sell its products, and that if this approach ceases to be effective, commercialisation may be adversely affected and the products may not be profitable.
• Clinical development can fail — The company describes drug development as a long, expensive and unpredictable process with a high risk of failure, with no guarantee that its products or candidates will succeed in ongoing or future trials or obtain regulatory approval, and warns that delays, suspensions and terminations in trials could increase costs and push out revenues.
• Patents can be successfully challenged — ACADIA discloses that if its patents are successfully challenged it may face generic competition before the expiry of its Orange Book-listed patents, that potential competitors have filed and may file ANDAs for generic versions of NUPLAZID seeking approval ahead of patent expiry, and that defending these rights is expensive and time consuming.
• Adoption and adherence are not guaranteed — The filing warns that the products may not gain maximal acceptance among physicians, patients, caregivers and the medical community, limiting revenue potential. It specifically notes that if patients do not adhere to the recommended dosing of DAYBUE, or titrate below the recommended dose, they may not experience the desired outcomes and physicians or patients may form negative beliefs about the drug and discontinue it.
• Results are expected to fluctuate and may need financing — The company expects its results of operations to fluctuate, which may make future performance hard to predict period to period, citing among other things the variation in gross-to-net adjustments driven by its Medicare Part D liability. It also discloses that it may require additional financing in the future and, if it cannot raise it, may be unable to fund its business plan and its research, development, commercial and manufacturing efforts.
• Drug pricing policy and trade measures — The company discloses exposure to healthcare cost-containment policy, including Most-Favored-Nation pricing initiatives, changes to the Medicare Drug Price Negotiation Program, Medicaid rebates, the 340B programme and pharmacy benefit manager practices, all of which could increase gross-to-net adjustments. It separately flags that international trade policies, including tariffs, sanctions and trade barriers, may adversely affect its business.

Die größten Kunden machen 82 % des Umsatzes aus

Concentration is extreme, because ACADIA's customers are intermediaries, not patients. The 10-K's concentration table lists five customers that each represented 10% or more of consolidated total gross revenues in 2025 — 34%, 13%, 12%, 12% and 11%, which together come to 82%; the same largest customer was 34% in 2024 and accounted for 36% of the accounts receivable balance at 31 December 2025. Separately, the company states that four US specialty pharmacies and distributors accounted for approximately 79% of NUPLAZID product revenue and 44% of total product revenue in 2025, while DAYBUE is sold in the US to a single wholesale distributor with specialty pharmacy services. This measures distribution, not end demand: the underlying prescriptions are spread across many physicians and patients, and the company says it specifies credit quality standards designed to limit exposure to any single party, with no allowance for credit losses required at year end. Substantially all revenue in 2025, 2024 and 2023 came from customers in North America.